Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression

Journal of Clinical Investigation

Volumn 122, Issue 10, 2012, Pages 3731-3736

  Weiss, Andreas ^a   Träger, Ulrike ^b   Wild, Edward J ^b   Grueninger, Stephan ^a   Farmer, Ruth ^c   Landles, Christian ^d   Scahill, Rachael I ^b   Lahiri, Nayana ^b   Haider, Salman ^b   Macdonald, Douglas ^e   Frost, Chris ^c   Bates, Gillian P ^d   Bilbe, Graeme ^a   Kuhn, Rainer ^a   Andre, Ralph ^b   Tabrizi, Sarah J ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e CHDI MANAGEMENT CHDI FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUNTINGTIN; MUTANT PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; B LYMPHOCYTE; CAUDATE NUCLEUS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; FLUORESCENCE RESONANCE ENERGY TRANSFER; FRAGMENTATION REACTION; GENE MUTATION; HETEROZYGOTE; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; IMMUNE SYSTEM; IMMUNOASSAY; IMMUNOCOMPETENT CELL; MONOCYTE; NON INVASIVE PROCEDURE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCORING SYSTEM; T LYMPHOCYTE;

ATROPHY; B-LYMPHOCYTES; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CAUDATE NUCLEUS; DISEASE PROGRESSION; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMANS; HUNTINGTON DISEASE; IMMUNOPRECIPITATION; LEUKOCYTES; MONOCYTES; MUTATION; NERVE TISSUE PROTEINS; T-LYMPHOCYTES;

EID: 84867148826     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI64565     Document Type: Article

References (24)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993;72(6):971-983.
2. de Almeida LP, Ross CA, Zala D, Aebischer P, Déglon N. Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J Neurosci. 2002;22(9):3473-3483.
3. Kim J, Bordiuk OL, Ferrante RJ. Experimental models of HD and reflection on therapeutic strategies. Int Rev Neurobiol. 2011;98:419-481.
4. MacDonald ME, Gines S, Gusella JF, Wheeler VC. Huntington's disease. Neuromolecular Med. 2003;4(1-2):7-20.
5. van der Burg JM, Björkqvist M, Brundin P. Beyond the brain: widespread pathology in Huntington's disease. Lancet Neurol. 2009;8(8):765-774.
6. Dalrymple A, et al. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J Proteome Res. 2007;6(7):2833-2840. (Pubitemid 47122377)
7. Björkqvist M, et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med. 2008;205(8):1869-1877.
8. Wild E, et al. Abnormal peripheral chemokine profile in Huntington's disease. PLoS Curr. 2011;3:RRN1231.
9. Zwilling D, et al. Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell. 2011;145(6):863-874.
10. Kwan W, et al. Bone marrow transplantation confers modest benefits in mouse models of Huntington's disease. J Neurosci. 2012;32(1):133-142.
11. Tai YF, et al. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain. 2007;130(pt 7):1759-1766. (Pubitemid 47343790)
12. Weiss A, et al. Microtiter plate quantification of mutant and wild-type huntingtin normalized to cell count. Anal Biochem. 2011;410(2):304-306.
13. Myers RH. Huntington's disease genetics. NeuroRx. 2004;1(2):255-262. (Pubitemid 46589355)
14. Penney JB, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol. 1997;41(5):689-692. (Pubitemid 27212666)
15. Tabrizi SJ, et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol. 2012;11(1):42-53.
16. Whitelaw DM. The intravascular lifespan of monocytes. Blood. 1966;28(3):455-464.
17. MacDonald ME, et al. Gametic but not somatic instability of CAG repeat length in Huntington's disease. J Med Genet. 1993;30(12):982-986. (Pubitemid 23356864)
18. Landles C, et al. Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. J Biol Chem. 2010;285(12):8808-8823.
19. DiFiglia M, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 1997;277(5334):1990-1993. (Pubitemid 27449140)
20. Vonsattel JP, Keller C, Cortes Ramirez EP. Huntington's disease - neuropathology. Handb Clin Neurol. 2011;100:83-100.
21. Toneff T, et al. Comparison of huntingtin proteolytic fragments in human lymphoblast cell lines and human brain. J Neurochem. 2002;82(1):84-92. (Pubitemid 34755252)
22. Leung KK, et al. Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: tissue-specific intensity normalization and parameter selection. Neuroimage. 2010;50(2):516-523.
23. White HA. White HA. Heteroskedasticity-consistent covariance matrix estimator and a direct test for heteroskedasticity. Econometrica. 1980;48(4):817-838.
24. Huber PJ. The behavior of maximum likelihood estimates under nonstandard conditions. In: Le Cam LM, Neyman J, eds. Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability. Vol. 1: Statistics. Berkeley, California, USA: University of California Press; 1967:221-233.